抗體市場：按藥物類型、疾病、最終用戶和地區分類

Antibodies Market, By Drug Type, by Disease Indication By End User, And by Region

出版日期: 2026年04月28日 | 出版商:

Coherent Market Insights | 英文 250+ Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

預計到2026年，抗體市場規模將達到3,230.437億美元，到2033年將達到7,647.148億美元。預計從2026年到2033年，其複合年成長率將達到13.1%。

報告範圍		報告詳情
基準年：	2025	2026年市場規模：	3230.437億美元
歷史數據時期：	2020年至2024年	預測期：	2026年至2033年
2026年至2033年預測期間的複合年成長率：	13.10%	2033年市場規模預測：	7647.148億美元

抗體被用於治療癌症、自體免疫疾病、血液疾病和感染疾病。癌症發生率的上升預計將為製造商創造巨大的市場成長機會。抗體產品屬於生物製藥。生物製藥製造商必須獲得美國食品藥物管理局(FDA) 的批准（類似藥品核准）才能將其產品推向市場。然而，與藥品不同的是，生物製藥必須向生物製藥評估和研究中心 (CBER) 提交生物製藥許可申請 (BLA)。此外，各國政府部門正致力於透過推動改革來控制和降低藥品價格。例如，2019 年 2 月，美國政府試圖透過限制藥品製造商與分銷通路合作夥伴（例如藥品福利管理機構 (PBM)）簽訂的合約來降低聯邦醫療保險 (Medicare) 患者的自付費用（這些合約會導致藥品標價上漲）。

市場動態

預計在預測期內，市場主要參與者擴大採用非內部成長策略（例如聯盟和夥伴關係）來擴展產品系列，這將推動市場成長。例如，2020年1月，生物製藥公司MorphoSys AG與跨國製藥公司Incyte Corporation合作，共同開發和商業化MorphoSys的Tafasitamab，這是一種靶向CD19的人源化Fc修飾單株抗體。

本研究的主要特點：

本研究揭示了各個細分市場的潛在商機，並為該市場說明了一個具有吸引力的投資提案矩陣。
此外，本研究還深入分析了市場促進因素、限制因素、機會、新產品發布和批准、市場趨勢、區域展望以及主要參與者採取的競爭策略。
本研究根據以下參數介紹了全球抗體市場主要公司的概況：公司概況、產品系列、主要亮點、財務績效和策略。
本報告提供的見解將使企業行銷負責人和經營團隊能夠就未來的產品發布、產品類型升級、市場擴張和行銷策略做出明智的決策。
這份全球抗體市場報告的目標受群眾外包括產業內的各種相關人員，例如投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
相關人員可以透過分析全球抗體市場中使用的各種策略矩陣來簡化決策過程。

北美洲
- 美國
- 加拿大
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲國家
歐洲
- 英國
- 德國
- 義大利
- 法國
- 西班牙
- 俄羅斯
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- ASEAN
- 澳洲
- 韓國
- 其他亞太國家
中東
- GCC
- 以色列
- 其他中東國家
非洲
- 北非
- 中非
- 南非

第8章競爭情勢

Novartis International AG
Hoffmann-La Roche Ltd.
Johnson & Johnson Services, Inc.
Takeda Pharmaceutical Company Limited
Amgen Inc.
Biogen Inc.
Bristol-Myers Squibb Company
AbbVie Inc.
Sanofi SA
Eli Lilly and Co.
Iovance Biotherapeutics, Inc.
Ultragenyx Pharmaceutical Inc.
Kyowa Kirin Co., Ltd.

第9章

調查方法
關於本公司

簡介目錄

Product Code: CMI2629

Antibodies Market is estimated to be valued at USD 3,23,043.7 Mn in 2026 and is expected to reach USD 7,64,714.8 Mn by 2033, growing at a compound annual growth rate (CAGR) of 13.1% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 3,23,043.7 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	13.10%	2033 Value Projection:	USD 7,64,714.8 Mn

Antibodies are used in therapeutic applications for the treatment of diseases such as cancer, autoimmune diseases, hematological diseases, infectious diseases, and others. The increasing prevalence of cancer is expected to create lucrative opportunities for the growth of manufacturers in the market. Antibodies products come under biological therapeutic products. Biologic manufacturers require approval (similar to pharma drug approval) from the U.S. Food & Drug Administration prior to bringing the product to the market. However, unlike drugs, biologics require Biologics License Applications (BLA) to be filed with the Center for Biologics Evaluation and Research (CBER). Moreover, various government authorities are focused on controlling/lowering drug prices by adding reforms. For instance, the U.S. government is seeking to lower patients' out-of-pocket spending in Medicare by curbing deals that drug manufacturers make with its distribution channel partners such as pharmacy benefit managers, in February 2019 (these deals are responsible for increasing list price of drugs).

Market Dynamics

Increasing adoption of inorganic growth strategies, such as collaboration and partnership by key players in the market to expand their product portfolio, is expected to drive market growth over the forecast period. For instance, in January 2020, MorphoSys AG, biopharmaceutical company collaborated with Incyte Corporation a multinational pharmaceutical company for the development and commercialization of MorphoSys' tafasitamab, a humanized Fc-engineered monoclonal antibody against CD19.

Key features of the study:

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global antibodies market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study are Key companies covered as a part of this study include Novartis AG, F. Hoffmann-La Roche Ltd., Johnson & Johnson Services, Inc., Takeda Pharmaceutical Company Limited, Amgen Inc., Biogen Inc., Bristol-Myers Squibb Company, AbbVie Inc., Sanofi, Eli Lilly and Co., Iovance Biotherapeutics, Inc., Ultragenyx Pharmaceutical Inc., and Kyowa Kirin Co., Ltd.
Insights from this report will allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global antibodies market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global antibodies market

Detailed Segmentation:

Global Antibodies Market, By Drug Type (Revenue, USD Mn, 2021 - 2033)
Monoclonal antibodies
Polyclonal antibodies
Antibody-drug complexes (ADCs)
Global Antibodies Market, By Disease Indication (Revenue, USD Mn, 2021 - 2033)
CNS Disorders
Cardiovascular Diseases
Cancer
Autoimmune Disorders
COVID-19
Others
Global Antibodies Market, By End User (Revenue, USD Mn, 2021 - 2033)
Hospitals
Long-term Care Facilities
Research institutes
Global Antibodies Market, By Region (Revenue, USD Mn, 2021 - 2033)
North America
- By Country:
  - U.S.
  - Canada
Latin America
- By Country:
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- By Country:
  - Germany
  - U.K.
  - France
  - Italy
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- By Country
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- By Country:
  - GCC
  - Israel
  - Rest of Middle East
Africa
- By Country/Region:
  - South Africa
  - Central Africa
  - North Africa
Company Profiles
Novartis International AG*
- Company Highlights
- Products Portfolio
- Key Highlights
- Financial Performance
- Strategies
F. Hoffmann-La Roche Ltd.
Johnson & Johnson Services, Inc.
Takeda Pharmaceutical Company Limited
Amgen Inc.
Biogen Inc.
Bristol-Myers Squibb Company
AbbVie Inc.
Sanofi S.A.
Eli Lilly and Co.
Iovance Biotherapeutics, Inc.
Ultragenyx Pharmaceutical Inc.
Kyowa Kirin Co., Ltd.

"*" marked represents similar segmentation in other categories in the respective section.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Drug Type
- Market Snapshot, By Disease Indication
- Market Snapshot, By End User
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Key Highlights
- Product Launch
- Technological Advancements
- PEST Analysis
- Regulatory Scenario
- Mergers and Acquisitions

4. Global Antibodies Market, By Drug Type, 2021-2033, (US$ Million)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Monoclonal Antibodies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
Polyclonal Antibodies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
Antibody-drug complexes (ADCs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)

5. Global Antibodies Market, By Disease Indication, 2021-2033, (US$ Million)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
CNS Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
Cardiovascular Diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
Autoimmune Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)

6. Global Antibodies Market, By End User, 2021-2033, (US$ Million)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021-2033
- Segments Trends
Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
Long-term Care Facilities
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
Research institutes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)

7. Global Antibodies Market, By Region, 2021-2033, (US$ Million)

Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2022-2033
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication , 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021-2033, (US$ Million)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication , 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021-2033, (US$ Million)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication , 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021-2033, (US$ Million)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication , 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021-2033, (US$ Million)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication , 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021-2033, (US$ Million)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication , 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021-2033, (US$ Million)
  - North Africa
  - Central Africa
  - South Africa

8. Competitive Landscape

Novartis International AG*
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Hoffmann-La Roche Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Johnson & Johnson Services, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Takeda Pharmaceutical Company Limited
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Amgen Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Biogen Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Bristol-Myers Squibb Company
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
AbbVie Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Sanofi S.A.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Eli Lilly and Co.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Iovance Biotherapeutics, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Ultragenyx Pharmaceutical Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Kyowa Kirin Co., Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies